The vaccines against human immunodeficiency virus (HIV) can be made effective by a protein can also prevent transmission of the virus, say researchers, including one of an Indian-origin.
A protein called Polyglutamine-binding protein 1 (PQBP1) acts as a front-line sensor to recognize HIV and initiates an immune response to the virus, the results showed.
Initial HIV Care at Home may Increase Use of ART
Offering optional home care initiation after HIV self testing could be linked to a significant increase in the number of adults initiating antiretroviral therapy compared to standard HIV care
Advertisement
When the protein encounters the virus, it starts a program that triggers an overall protective environment against infection and enhances the production of virus-specific antibodies.
"Vaccines work by teaching the immune system to react by mimicking a natural infection," said lead author Sunnie Yoh, post-doctoral fellow in the lab of Sumit Chanda, director of the immunity and pathogenesis program at Sanford-Burnham Medical Research Institute in the US.
"Current approaches to HIV vaccine development have so far yielded little fruit, partly because of the lack of an effective vaccine adjuvant. Adjuvants promote a robust immune response to vaccines and are critical to eliciting long-lasting immunity," Chanda said.
"Our study identifies a promising new target for a vaccine adjuvant that could advance the development of HIV vaccines and prevent infection."
Vaccines against HIV are being developed, and they are in various stages of clinical trial but at present none has proven effective, according to the World health Organization (WHO).
Designing a drug that mimics the interface between HIV and PQBP1 would allow an HIV vaccine to more effectively re-create an immune environment that mirrors real infection, Yoh said.
The research was published online in the journal Cell.
Source: Medindia
Advertisement
"Current approaches to HIV vaccine development have so far yielded little fruit, partly because of the lack of an effective vaccine adjuvant. Adjuvants promote a robust immune response to vaccines and are critical to eliciting long-lasting immunity," Chanda said.
"Our study identifies a promising new target for a vaccine adjuvant that could advance the development of HIV vaccines and prevent infection."
Vaccines against HIV are being developed, and they are in various stages of clinical trial but at present none has proven effective, according to the World health Organization (WHO).
Designing a drug that mimics the interface between HIV and PQBP1 would allow an HIV vaccine to more effectively re-create an immune environment that mirrors real infection, Yoh said.
The research was published online in the journal Cell.
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest AIDS/HIV News
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
